Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sirna Therapeutics Inc -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (289)	11/30/1999 3:43:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 562

Cancer Companies Convene in Seattle Dec. 11 to Showcase Science, Finances At Investors Forum SEATTLE, Nov. 30 /PRNewswire/ -- In the unpleasant world of cancer, the diagnosis that stirs the most fear is "we believe it's pancreatic cancer." From initial diagnosis to death is often no more than four months. Currently there is no effective treatment for pancreatic cancer. But numerous companies are hard at work trying to combat this killer. One considered at the leading edge of the battle is SuperGen Inc. (Nasdaq: SUPG), an emerging pharmaceutical company based in San Ramon, CA. SuperGen's Rubitecan(R) is a chemotherapy pill currently in Phase III clinical testing for the treatment of pancreatic cancer and in Phase II testing for the treatment of 11 additional tumor types. If trials are concluded successfully and Rubitecan receives necessary Food and Drug Administration approvals, it could be available in 2001. Another presenting company, biotech "granddaddy" Genenetch (NYSE: DNA), last year introduced Rituxan(R) with partner IDEC Pharmaceuticals (Nasdaq: IDPH). The companies' groundbreaking research and development produced the first new, single-agent therapy for non-Hodgkin's lymphoma in 11 years and the first monoclonal antibody approved by the FDA for the treatment of cancer in the U.S. Senior executives from SuperGen, Genentech and other biopharma companies involved in developing cancer treatments and products will be presenting their stories to individual investors at the Third Annual Informed Investors Cancer/Biotechnology Stocks Forum Saturday, Dec. 11 at the downtown Hilton in Seattle. The gathering is a combined scientific-financial conference. Attendees focused on science can preview biotechnological treatments for cancer treatments evolving in laboratories worldwide. Similarly, investors will find it informative and worthwhile to hear firsthand from companies on the cutting edge of biopharma research, development and product commercialization. Kicking off the Forum is an address -- "Accelerating Drug Discovery With Model Organisms" -- by Lee Hartwell, Ph.D., President and Director of Seattle's elite Fred Hutchinson Cancer Research Center. Dr. Hartwell is a renowned cancer researcher and will frame the day's activities. Offering specific insights into the corporate battery of technologies, therapeutics and latest developments waging war on cancer will be senior executives from an important lineup of companies scheduled to present, including Seattle-based Cell Therapeutics (Nasdaq: CTIC), Corixa Corp. (Nasdaq: CRXA) and Targeted Genetics (Nasdaq: TGEN). Also presenting are: Avax Technologies (Nasdaq: AVXT); Genzyme Molecular Oncology (Nasdaq: GZMO); Ilex Oncology (Nasdaq: ILXO); Isis Pharmaceuticals (Nasdaq: ISIP); Matrix Pharmaceutical (Nasdaq: MATX); Ribozyme Pharmaceuticals (Nasdaq: RZYM); and Vical (Nasdaq: VICL). The investment perspective will be provided by Lissa Morganthaler, biotech analyst for the Murphy New World Biotechnology Fund, and Al Rauch, Ph.D., CFA, Senior Vice President-Health Care Technology at First Union Securities. The Forum runs from 8:30-4 p.m. Cost is $40 prepaid including lunch ($10 of each admission is donated to the Hutchinson Center); $55 at the door. Register at www.informedinvestors.com or call 800-992-4683. InformedInvestors.com is the leading producer of online and offline industry-specific investment conferences for individual investors and offers a growing stable of resources for in-depth sector-analysis. SOURCE InformedInvestors.com CO: InformedInvestors.com ST: Washington, California IN: MTC FIN BIO SU: 11/30/1999 15:25 EST prnewswire.com